IRIS UniCatt

Guidi, Luisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.864
EU - Europa 2.613
AS - Asia 1.889
SA - Sud America 402
AF - Africa 57
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 7.830
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.799
DE - Germania 998
SG - Singapore 884
CN - Cina 524
SE - Svezia 461
BR - Brasile 342
UA - Ucraina 239
IT - Italia 201
FR - Francia 173
GB - Regno Unito 142
IE - Irlanda 128
IN - India 110
ID - Indonesia 84
VN - Vietnam 82
FI - Finlandia 68
PL - Polonia 47
TR - Turchia 45
RU - Federazione Russa 43
CA - Canada 31
AR - Argentina 25
BD - Bangladesh 25
BE - Belgio 25
HK - Hong Kong 22
JP - Giappone 18
MX - Messico 18
ES - Italia 17
ZA - Sudafrica 16
NL - Olanda 14
IQ - Iraq 13
IR - Iran 13
AT - Austria 11
VE - Venezuela 10
CI - Costa d'Avorio 9
EC - Ecuador 9
PK - Pakistan 9
SA - Arabia Saudita 9
MA - Marocco 8
CZ - Repubblica Ceca 7
KR - Corea 6
HU - Ungheria 5
PH - Filippine 5
PT - Portogallo 5
UY - Uruguay 5
UZ - Uzbekistan 5
BG - Bulgaria 4
CH - Svizzera 4
CO - Colombia 4
DZ - Algeria 4
GR - Grecia 4
IL - Israele 4
JM - Giamaica 4
LT - Lituania 4
NP - Nepal 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
EG - Egitto 3
JO - Giordania 3
KE - Kenya 3
LV - Lettonia 3
OM - Oman 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
BZ - Belize 2
CG - Congo 2
CL - Cile 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
KZ - Kazakistan 2
LB - Libano 2
PY - Paraguay 2
TW - Taiwan 2
AQ - Antartide 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GY - Guiana 1
HN - Honduras 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
NI - Nicaragua 1
NO - Norvegia 1
PE - Perù 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
Totale 7.826
Salva come PNG Salva come JPEG
Città #
Chandler 554
Singapore 416
Ashburn 249
Jacksonville 167
Dublin 124
Beijing 123
San Mateo 122
New York 111
Dearborn 107
Ann Arbor 101
Los Angeles 77
Jakarta 75
Nanjing 71
Munich 64
Wilmington 64
Cattolica 59
Nürnberg 59
Boston 55
Milan 41
Hefei 39
Houston 36
Bremen 34
Princeton 34
Lawrence 33
Izmir 27
Moscow 27
Seattle 25
Marseille 24
São Paulo 24
Warsaw 24
Brussels 23
Frankfurt am Main 22
Lancaster 22
Buffalo 21
Dallas 21
Fairfield 21
Kraków 21
Nanchang 20
Ho Chi Minh City 19
Hong Kong 19
Woodbridge 19
Redwood City 18
Shenyang 17
Hangzhou 16
Hanoi 16
Augusta 15
Guangzhou 15
Boardman 14
Changsha 14
Helsinki 14
London 14
Tokyo 14
Leawood 13
Mountain View 12
Rio de Janeiro 12
Rome 12
Shanghai 12
Brasília 11
Hebei 11
Jiaxing 11
Stockholm 11
Detroit 10
Kunming 10
Pune 10
The Dalles 10
Tianjin 10
Toronto 10
Abidjan 9
Belo Horizonte 9
Hyderabad 9
Johannesburg 9
Norwalk 9
Redmond 9
San Francisco 9
Zhengzhou 9
Ardabil 8
Brooklyn 8
Chicago 8
Costa Mesa 8
Turku 8
Andover 7
Ankara 7
Baghdad 7
Cagliari 7
Düsseldorf 7
Kent 7
Lauterbourg 7
Nuremberg 7
San Jose 7
University Park 7
Atlanta 6
Denver 6
Duque de Caxias 6
Fremont 6
Jinan 6
Mexico City 6
Ottawa 6
Sacramento 6
Seoul 6
Washington 6
Totale 3.768
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 350
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 190
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 186
Early atherosclerosis in patients with inflammatory bowel disease. 183
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 180
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 175
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 173
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 172
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 160
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 157
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 156
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 154
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 152
Sonography of the small bowel after oral administration of fluid: an assessment of the diagnostic value of the technique 150
Ileal Crohn's disease: CEUS determination of activity 143
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 139
Use of infliximab in particular clinical settings: management based on current evidence. 136
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 136
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 135
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 127
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 126
Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy 125
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 125
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 124
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 117
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 114
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 113
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 113
Management of perianal fistulas in Crohn's disease: an up-to-date review 112
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 109
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 107
Paradoxical arthritis occurring during anti-TNF in patients with Inflammatory Bowel Disease: histological and immunological features of a complex synovitis. 103
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 102
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 99
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 98
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 98
AID in aging and autoimmune diseases 95
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 94
Mucosal healing in ulcerative colitis: surveillance or colectomy? 94
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 94
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 94
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 92
Neuropeptide Y plasma levels and immunological changes during academic stress 90
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 88
Adalimumab in active ulcerative colitis: a "real-life" observational study 87
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 86
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 86
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 82
[Soluble factors with immunosuppressive activity in human neoplasms] 81
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 78
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 78
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 78
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 78
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 76
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 76
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. 75
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 74
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 73
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 73
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 72
The Italian registry of therapeutic apheresis: Granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study 71
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data 68
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 68
Linking estrogen receptor β expression with inflammatory bowel disease activity 68
Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis 67
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. 67
Watery stools and metabolic acidosis 67
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 66
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. 65
Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: A single-centre experience 50
Serum levels of metalloproteinases and their inhibitors in nonalcoholic steatohepatitis 50
Small bowel diseases 31
Small bowel diseases 29
Totale 7.900
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.781
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.781
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021280 0 0 0 0 0 11 44 17 60 17 117 14
2021/2022646 55 45 9 107 16 14 8 116 19 27 106 124
2022/20231.376 184 193 96 233 109 159 54 115 172 10 33 18
2023/2024639 30 185 18 46 17 112 25 38 10 22 62 74
2024/20251.116 23 42 117 18 122 46 37 65 156 123 199 168
2025/20261.619 494 70 154 337 510 54 0 0 0 0 0 0
Totale 7.900